Pacific Edge

Dunedin-based cancer diagnostic company Pacific Edge is to receive $4.5 million in government grants towards research and development over the next three years.

Following a stellar year hitting targets and milestones, listed Dunedin bio-tech company Pacific Edge has been named Otago Daily Times Business of The Year 2013. Business reporter Simon Hartley profiles Pacific Edge's decade of persistence.

Cancer diagnostic company Pacific Edge became a Dunedin-based superstar this week as its share price briefly reached $1.75 on the back of several good news announcements.

The recent volatility in Pacific Edge's share price was surreal, chief executive David Darling said yesterday.

A massive share spike followed Dunedin-based cancer diagnostic company Pacific Edge announcing it is signing up a key US client, FedMed, a national health network servicing 40 million Americans.

Shares in Dunedin-based cancer diagnostic company Pacific Edge briefly hit an all time high of 79c yesterday, following the appointment of a non-executive director to its US subsidiary.

Dunedin bio-tech company Pacific Edge has reported an expected loss of $3.24 million for the half year as it awaits US regulatory approval to open its just completed $4.5 million laboratory in Pennsylvania.

The past 12 months have been a thrilling ride for Pacific Edge, but chief executive David Darling said yesterday that more excitement was on the way for the company and its shareholders.

Dunedin-based Pacific Edge says it has been awarded a patent in Singapore for its colorectal cancer prognostic technology, and anticipates the patent will be issued in other targeted countries in the next 12 to 24 months.

Dunedin-based biotech company Pacific Edge has announced another contract for its expanding diagnostic bladder cancer test, which appears to be going from strength to strength.

Dunedin-based biotech company Pacific Edge is setting up its United States commercial laboratory and headquarters for its diagnostic bladder cancer test in Pennsylvania, within the Hershey Centre for Applied Research, a university and technology research facility.

Dunedin-based cancer diagnostic company Pacific Edge has posted a half-year loss of $1.7 million, mainly through costs associated with undertaking clinical trials and further product development.

Pacific Edge shareholders can expect to see the Dunedin-based company concentrate on getting its cancer diagnostic products into the United States, backed by potentially more than $20 million in new funding.

Biotech company Pacific Edge, of Dunedin, is confident of securing several licence agreements this year for its mainstay bladder cancer detection test - in development now for more than seven years.